In the biotech market,
Prologis (PLD) has been a well-discussed stock. Various investment advisory services such as
Gryphon Financial Partners, Steward Partners Investment Advisory, and Hsbc Holdings PLC have increased their holdings in Prologis. Prologis has showcased solid financials, with
Q1-Q4 2023 earnings often surpassing market estimates. Meanwhile,
TD Asset Management and Advisory Services Network sold sizeable shares. Prologis held multiple events, including the
Investor Forum and the Annual Stockholders Meeting. The company also announced executive retirements and new appointments. Despite
Mizuho lowering Prologis' price target to $120, Wall Street analysts maintain an optimistic viewpoint recommending the stock as a strong buy. Prologis has made significant strides toward its green initiative, reaching its
500-megawatt solar milestone. However, Prologis did
trim its 2024 guidance which stirred reactions in the market. The firm's deep associations with AI and EV have been essential in holding a strong market position. Prologis, catapulting it to be an excellent long-term investment, boasts
double-digit dividend growth. The company’s financial forecast predicts
Q1 2025 earnings at $1.42 per share.
Prologis PLD News Analytics from Tue, 18 Jul 2023 07:00:00 GMT to Sun, 02 Jun 2024 16:21:09 GMT -
Rating 7
- Innovation 1
- Information 8
- Rumor -5
